Psychedelic Compounds in Adult Psychiatry: Current Status and Recommendations

Introduction to Psychedelic Compounds

The U.S. Department of Veterans Affairs and U.S. Department of Defense clinical practice guidelines recommend against psilocybin for major depressive disorder treatment outside research settings, based on an evidence base consisting of only one small study with 27 participants 1
Psilocybin lacks any regulatory framework for clinical use, unlike FDA-approved alternatives such as ketamine/esketamine, which have Risk Evaluation and Mitigation Strategy (REMS) requirements and standardized safety protocols 1

Psilocybin therapy carries significant risk of psychotic events and harmful behaviors, particularly when patients lack appropriate guidance throughout treatment 1
Patients with history of psychotic disorders or active suicidal ideation must be excluded from treatment 1
Microdosing studies reveal dose-dependent effects including increased blood pressure, heart rate, pupil changes, galvanic skin responses, and autonomic changes 2, 3

The most frequently reported side effects are typically mild, dose-dependent, and short-lived, including headaches, insomnia, physical discomfort, and overstimulation 2, 4
Approximately 6% of microdosers experience negative physiological effects 2

Psychedelic therapy requires 8-12 hours of continuous healthcare provider guidance during dosing sessions, extensive preparation sessions before dosing, structured psychotherapeutic support integrated with dosing, and continuous monitoring throughout the entire session 1
Implementation requires redefinition of psychotherapeutic processes and new treatment infrastructure, including rigorous screening protocols and institutional review board oversight 1

Microdosing involves taking sub-perceptual doses regularly to improve daily functioning, reduce anxiety, and enhance mood and cognition 4, 5
Despite common anecdotal claims, consistent evidence shows microdosing leads to changes in subjective awareness, but a systematic review found significant methodological limitations 4, 5, 6
Self-rated intensity of drug effects was the only measure differentiating microdoses from placebo after controlling for expectation in self-blinded prospective studies 3, 4

Psychedelic compounds should only be used within approved clinical trials with institutional review board oversight until larger, well-designed randomized controlled trials establish their risk-benefit profile 1
The acceptable benefit-risk profile exists only in highly controlled research settings with integrated structured psychotherapeutic support, careful patient screening, and continuous monitoring during entire sessions 1